Novartis invests in 2 US radiopharmaceutical facilities

Novartis is making two investments in new radiopharmaceutical manufacturing sites in the US. The Swiss pharmaceutical giant will open a third US radioligand plant in Carlsbad, California, to serve the West Coast. The company also plans to add a new radioligand facility at its site in Indianapolis. Novartis currently has two radiotherapies on the market, Pluvicto and Lutathera, which last year generated revenue of $980 million and $458 million, respectively.